Matthew Angel bought $500k of TPST
CEO and President at Tempest Therapeutics, Inc.. 231,482 shares at an average of $2.16, traded Mar 24, 2026, filed Jun 23, 2026.
Score components
- +25RoleCEO
- +18Trade size$500k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-279703, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | POpen-market purchase Common Stockindirect: By Factor Bioscience Inc. | +231,482 | $2.16 | $500k | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | POpen-market purchase Series A Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
| Mar 24, 2026 | POpen-market purchase Series B Warrant (right to buy)derivativeindirect: By Factor Bioscience Inc. | +231,482 | - | - | 231,482 | Jun 23, 2026 |
Related signals
Other insiders at Tempest Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | TPSTbuy Tempest Therapeutics, Inc. | Matthew Angel CEO and President | $500k 231,482 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.